Objective: To investigate the utility of the MANAGE PD tool in routine clinical care in Germany and the planned next steps after the tool recommendation.
Background: Making informed decisions to aid timely management of Parkinson’s Disease (MANAGE PD) is a registered web-based (managepd.eu) medical device to assist physicians identifying PD patients with insufficient control on oral medication. Following completion of both sections of the questionnaire, patients are categorized based on a validated algorithm. In category (cat) 1 patients’ symptoms are well controlled under the current treatment. In cat 2 patients may benefit from further oral treatment optimization and in cat 3 patients may benefit from device-aided therapies (DAT).
Method: This observational, cross-sectional, non-interventional study was conducted in 19 neurology centers in Germany. The study population consisted of adult patients diagnosed with PD who attended a routine visit during which all data were collected. The first section of the questionnaire was independently filled out by both the patient and the physician. The data were analyzed and presented using descriptive statistics. The Kappa coefficient was used to measure agreement between the patient and the physician in section 1.
Results: Of 278 patients, 18,0 % were assigned to cat 1; 45,0 % to cat 2; and 37,1 % to cat 3 using the tool. The physician’s assessment of the categories was 27 %; 48 % and 26 %; respectively. The agreement between the physician’s and patient’s responses in section 1 was high (κ coefficient between 0,60 and 0,84 depending on the question). Changes in treatment were planned for 47 % of patients in cat 2 and 62 % in cat 3. DAT was planned for 35 % of patients in cat 3. The most common reasons for not planning treatment change in cat 2 and 3 were patient not wanting change (43%), other (31%), and no change needed (23%). The most common personal reasons for not initiating DAT were fear (27 %) and invasiveness (19 %).
Conclusion: The high level of agreement between the patient and the physician regarding section 1 suggests that patients can report reliable and useful information regarding their motor state. However, their reluctance concerning the recommended treatment optimization was high.
To cite this abstract in AMA style:M. Südmeyer, D. Pedrosa, F. Siebecker, C. Arlt, J. Kopra, W. Jost. Real-world utility of MANAGE PD tool by physicians and patients in Germany [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/real-world-utility-of-manage-pd-tool-by-physicians-and-patients-in-germany/. Accessed September 23, 2023.
« Back to 2023 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/real-world-utility-of-manage-pd-tool-by-physicians-and-patients-in-germany/